MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

SpringWorks Therapeutics Inc

Отворен

СекторЗдравеопазване

44.44 7.94

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

41.07

Максимум

46.21

Ключови измерители

By Trading Economics

Приходи

-24M

-77M

Продажби

12M

62M

EPS

-1.04

Марж на печалбата

-125.586

Служители

368

EBITDA

-23M

-80M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+75.93% upside

Дивиденти

By Dow Jones

Следващи печалби

1.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-1B

3.1B

Предишно отваряне

36.5

Предишно затваряне

44.44

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

SpringWorks Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.02.2025 г., 07:03 ч. UTC

Придобивния, сливания и поглъщания

Germany's Merck in Talks to Buy SpringWorks Therapeutics

10.02.2025 г., 16:38 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

SpringWorks Therapeutics Shares Rise on Report it May be Acquired

24.04.2025 г., 22:51 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24.04.2025 г., 20:54 ч. UTC

Придобивния, сливания и поглъщания

Merck KGaA: No Final Decision Has Been Taken; No Legally Binding Agreement Has Been Entered Into

24.04.2025 г., 20:50 ч. UTC

Придобивния, сливания и поглъщания

Merck KGaA Confirms Late-Stage Discussions With SpringWorks Therapeutics on Potential Acquisition for About 47c a Share

24.04.2025 г., 19:05 ч. UTC

Придобивния, сливания и поглъщания

Merck KGaA Expected to Pay Close to $47 a Share for SpringWorks, Sources Say -- WSJ

24.04.2025 г., 19:05 ч. UTC

Придобивния, сливания и поглъщания

Merck KGaA, SpringWorks Deal Expected to Be Finalized as Soon as Monday, Sources Say -- WSJ

24.04.2025 г., 19:05 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- WSJ

24.04.2025 г., 19:05 ч. UTC

Придобивния, сливания и поглъщания

Merck KGaA Nears Roughly $3.5 Billion Takeover of SpringWorks Therapeutics, Sources Say -- WSJ

11.02.2025 г., 10:54 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk

11.02.2025 г., 10:52 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

SpringWorks Therapeutics Inc Прогноза

Ценова цел

By TipRanks

75.93% нагоре

12-месечна прогноза

Среден 72.5 USD  75.93%

Висок 84 USD

Нисък 63 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за SpringWorks Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

8

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

37.9899 / N/AПодкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.